Quick Answer
MBX Biosciences, Inc. reported R&D Expense of $79.16 million for fiscal year 2025.
MBX Biosciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $79.16M | +37.9% |
| 2024 | $57.41M | +101.2% |
| 2023 | $28.53M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.27M | +15.1% | +8.7% |
| June 30, 2025 | $17.72M | +23.1% | -20.9% |
| March 31, 2025 | $22.41M | +102.8% | +33.8% |
| September 30, 2024 | $16.75M | +84.6% | +16.3% |
| June 30, 2024 | $14.40M | — | +30.3% |
| March 31, 2024 | $11.05M | — | +21.8% |
| September 30, 2023 | $9.07M | — | — |
- MBX Biosciences, Inc. showed an increase of +37.9% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, MBX Biosciences, Inc.’s r&d expense has grown by 177.4% (from $28.53 million to $79.16 million).
- The most recent figure is from MBX Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: